Platelets for advanced drug delivery in cancer

References

• ReFaey K, Tripathi S, Grewal SS, et al. Cancer mortality rates increasing vs cardiovascular disease mortality decreasing in the world: future implications. Mayo Clin Proc Innov Qual Outcomes. 2021 Jun;5(3):645–653.
   PubMedGoogle Scholar
• Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol. 2021 Oct;18(10):663–672.
   PubMed Web of Science ®Google Scholar
• Schlander M, Hernandez-Villafuerte K, Cheng CY, et al. How much does it cost to research and develop a new drug? A systematic review and assessment. Pharmacoeconomics. 2021 Nov;39(11):1243–1269.
   PubMed Web of Science ®Google Scholar
• Ocran Mattila P, Ahmad R, Hasan SS, et al. Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature. Front Public Health. 2021;9:628744.
   PubMed Web of Science ®Google Scholar
• de Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica. 2001 Apr;86(4):349–356.
   PubMed Web of Science ®Google Scholar
• Varon D, Shai E. Platelets and their microparticles as key players in pathophysiological responses. J Thromb Haemost. 2015 Jun;13(Suppl 1):S40–6.
   PubMed Web of Science ®Google Scholar
• Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. Platelets. 2015;26(3):199–211.
   PubMed Web of Science ®Google Scholar
• Gawaz M, Vogel S. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood. 2013 Oct 10;122(15):2550–2554.
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Zheng YW, Ohkohchi N. Novel functions of platelets in the liver. J Gastroenterol Hepatol. 2016 Apr;31(4):745–751.
   PubMed Web of Science ®Google Scholar
• Dovizio M, Bruno A, Contursi A, et al. Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications. Cancer Metastasis Rev. 2018 Sep;37(2–3):455–467.
   PubMed Web of Science ®Google Scholar
• Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other anti-platelet agents. Blood. 2018 Mar 8;131(16):1777–1789.
   PubMed Web of Science ®Google Scholar
• Li A, Chen J, Liang ZH, et al. Comparison of ultrastructural and nanomechanical signature of platelets from acute myocardial infarction and platelet activation. Biochem Biophys Res Commun. 2017 Apr 29;486(2):245–251.
   PubMed Web of Science ®Google Scholar
• Sanada C, Xavier-Ferrucio J, Lu YC, et al. Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction. Blood. 2016 Aug 18;128(7):923–933.
   PubMed Web of Science ®Google Scholar
• Miyawaki K, Iwasaki H, Jiromaru T, et al. Identification of unipotent megakaryocyte progenitors in human hematopoiesis. Blood. 2017 Jun 22;129(25):3332–3343.
   PubMed Web of Science ®Google Scholar
• Notta F, Zandi S, Takayama N, et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science. 2016 Jan 8;351(6269):aab2116.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Fraticelli AE, Wolock SL, Weinreb CS, et al. Clonal analysis of lineage fate in native haematopoiesis. Nature. 2018 Jan 11;553(7687):212–216.
   PubMed Web of Science ®Google Scholar
• Nakamura-Ishizu A, Matsumura T, Stumpf PS, et al. Thrombopoietin metabolically primes hematopoietic stem cells to megakaryocyte-lineage differentiation. Cell Rep. 2018 Nov 13;25(7):1772–1785.e6.
   PubMed Web of Science ®Google Scholar
• Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nature Med. 2004;10(1):64–71. DOI:10.1038/nm973
   PubMed Web of Science ®Google Scholar
• Stegner D, vanEeuwijk JMM, Angay O, et al. Thrombopoiesis is spatially regulated by the bone marrow vasculature. Nat Commun. 2017 Jul 25;8(1):127.
   PubMedGoogle Scholar
• Jiang J, Woulfe DS, Papoutsakis ET. Shear enhances thrombopoiesis and formation of microparticles that induce megakaryocytic differentiation of stem cells. Blood. 2014 Sep 25;124(13):2094–2103.
   PubMed Web of Science ®Google Scholar
• Potts KS, Farley A, Dawson CA, et al. Membrane budding is a major mechanism of in vivo platelet biogenesis. J Exp Med. 2020 Sep 7;217(9). DOI:10.1084/jem.20191206
   PubMed Web of Science ®Google Scholar
• Nishimura S, Nagasaki M, Kunishima S, et al. IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Bio. 2015 May 11;209(3):453–466.
   PubMed Web of Science ®Google Scholar
• Angénieux C, Maître B, Eckly A, et al. Time-dependent decay of mRNA and ribosomal RNA during platelet aging and its correlation with translation activity. PLoS ONE. 2016;11(1):e0148064–e0148064. DOI:10.1371/journal.pone.0148064
   PubMed Web of Science ®Google Scholar
• Mills EW, Green R, Ingolia NT. Slowed decay of mRnas enhances platelet specific translation. Blood. 2017 Apr 27;129(17):e38–48.
   PubMed Web of Science ®Google Scholar
• Huang J, Swieringa F, Solari FA, et al. Assessment of a complete and classified platelet proteome from genome-wide transcripts of human platelets and megakaryocytes covering platelet functions. Sci Rep. 2021 Jun 11;11(1):12358.
   PubMed Web of Science ®Google Scholar
• Parsons MEM, Szklanna PB, Guererro JA, et al. Platelet releasate proteome profiling reveals a core set of proteins with low variance between healthy adults. Proteomics. 2018 Jun 22;18(15):e1800219.
   PubMed Web of Science ®Google Scholar
• Velez P, Izquierdo I, Rosa I, et al. A 2D-DIGE-based proteomic analysis reveals differences in the platelet releasate composition when comparing thrombin and collagen stimulations. Sci Rep. 2015;5(1):8198. DOI:10.1038/srep08198
   PubMedGoogle Scholar
• Jonnalagadda D, Izu LT, Whiteheart SW. Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood. 2012 Dec 20;120(26):5209–5216.
   PubMed Web of Science ®Google Scholar
• Maynard DM, Heijnen HF, Horne MK, et al. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost. 2007 Sep;5(9):1945–1955.
   PubMed Web of Science ®Google Scholar
• Zufferey A, Schvartz D, Nolli S, et al. Characterization of the platelet granule proteome: evidence of the presence of MHC1 in alpha-granules. J Proteomics. 2014;101:130–140.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ruiz L, Valverde F, Jimenez-Nunez MD, et al. Organellar proteomics of human platelet dense granules reveals that 14-3-3zeta is a granule protein related to atherosclerosis. J Proteome Res. 2007 Nov;6(11):4449–4457.
   PubMed Web of Science ®Google Scholar
• Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999 Dec 1;94(11):3791–3799.
   PubMed Web of Science ®Google Scholar
• Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. DOI:10.1080/20013078.2018.1535750
   PubMed Web of Science ®Google Scholar
• Berckmans RJ, Lacroix R, Hau CM, et al. Extracellular vesicles and coagulation in blood from healthy humans revisited. J Extracell Vesicles. 2019;8(1):1688936. DOI:10.1080/20013078.2019.1688936
   PubMed Web of Science ®Google Scholar
• Arraud N, Linares R, Tan S, et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost. 2014 May;12(5):614–627.
   PubMed Web of Science ®Google Scholar
• Ponomareva AA, Nevzorova TA, Mordakhanova ER, et al. Intracellular origin and ultrastructure of platelet-derived microparticles. J Thromb Haemost. 2017 Aug;15(8):1655–1667.
   PubMed Web of Science ®Google Scholar
• De Paoli SH, Tegegn TZ, Elhelu OK, et al. Dissecting the biochemical architecture and morphological release pathways of the human platelet extracellular vesiculome. Cell Mol Life Sci. 2018 Oct;75(20):3781–3801.
   PubMed Web of Science ®Google Scholar
• Marcoux G, Laroche A, Hasse S, et al. Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules. Blood. 2021 Dec 23;138(25):2607–2620.
   PubMed Web of Science ®Google Scholar
• Cauwenberghs S, Feijge MA, Harper AG, et al. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton. FEBS Lett. 2006 Oct 2;580(22):5313–5320.
   PubMed Web of Science ®Google Scholar
• Agbani EO, van den Bosch MT, Brown E, et al. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation. 2015 Oct 13;132(15):1414–1424.
   PubMed Web of Science ®Google Scholar
• Agbani EO, Williams CM, Hers I, et al. Membrane ballooning in aggregated platelets is synchronised and mediates a surge in microvesiculation. Sci Rep. 2017 Jun 5;7(1):2770.
   PubMedGoogle Scholar
• Aatonen MT, Ohman T, Nyman TA, et al. Isolation and characterization of platelet-derived extracellular vesicles. J Extracell Vesicles. 2014;3(1):3. DOI:10.3402/jev.v3.24692
   Google Scholar
• Vismara M, Manfredi M, Zarà M, et al. Proteomic and functional profiling of platelet-derived extracellular vesicles released under physiological or tumor-associated conditions. Cell Death Discov. 2022 Nov 26;8(1):467.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Brunson A, Adesina O, et al. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022 Jan 11;6(1):307–320.
   PubMed Web of Science ®Google Scholar
• Li A, La J, May SB, et al. Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique us health care systems. J Clin Oncol. 2023 Jan 10:Jco2201542. DOI:10.1200/JCO.22.01542
   PubMedGoogle Scholar
• Zhang X, Lv Z, Yu H, et al. The clinicopathological and prognostic role of thrombocytosis in patients with cancer: a meta-analysis. Oncol Lett. 2017 Jun;13(6):5002–5008.
   PubMed Web of Science ®Google Scholar
• Rao XD, Zhang H, Xu ZS, et al. Poor prognostic role of the pretreatment platelet counts in colorectal cancer: a meta-analysis. Medicine (Baltimore). 2018 Jun;97(23):e10831.
   PubMed Web of Science ®Google Scholar
• Wang YH, Kang JK, Zhi YF, et al. The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: a systematic review and meta-analysis. Int J Surg. 2018 May;53:304–311.
   PubMed Web of Science ®Google Scholar
• Warny M, Helby J, Birgens HS, et al. Arterial and venous thrombosis by high platelet count and high hematocrit: 108 521 individuals from the copenhagen general population study. J Thromb Haemost. 2019 Nov;17(11):1898–1911.
   PubMed Web of Science ®Google Scholar
• Palacios-Acedo AL, Langiu M, Crescence L, et al. Platelet and cancer-cell interactions modulate cancer-associated thrombosis risk in different cancer types. Cancers (Basel). 2022 Jan 30;14(3):730.
   PubMed Web of Science ®Google Scholar
• Zhang SR, Yao L, Wang WQ, et al. Tumor-infiltrating platelets predict postsurgical survival in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018 Dec;25(13):3984–3993.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang M, Zhou T, et al. Role of platelet infiltration as independent prognostic marker for gastric adenocarcinomas. J Clin Lab Anal. 2020 Aug;34(8):e23320.
   PubMed Web of Science ®Google Scholar
• Cho MS, Li J, Gonzalez-Delgado R, et al. The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. Blood Adv. 2021;5(7):1947–1951. DOI:10.1182/bloodadvances.2020003410
   PubMed Web of Science ®Google Scholar
• Miao Y, Xu Z, Feng W, et al. Platelet infiltration predicts survival in postsurgical colorectal cancer patients. Int J Cancer. 2022 Feb 1;150(3):509–520.
   PubMed Web of Science ®Google Scholar
• Xu SS, Xu HX, Wang WQ, et al. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor. World J Gastroenterol. 2019 Nov 7;25(41):6248–6257.
   PubMed Web of Science ®Google Scholar
• Yu LX, Yan L, Yang W, et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nat Commun. 2014 Oct 28;5(1):5256.
   PubMedGoogle Scholar
• Adesanya MA, Maraveyas A, Madden L. Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography. Blood Coagul Fibrinolysis. 2017 Dec;28(8):602–611.
   PubMed Web of Science ®Google Scholar
• Takemoto A, Okitaka M, Takagi S, et al. A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. Sci Rep. 2017 Feb 8;7(1):42186.
   PubMedGoogle Scholar
• Qi C, Wei B, Zhou W, et al. P-selectin-mediated platelet adhesion promotes tumor growth. Oncotarget. 2015 Mar 30;6(9):6584–6596.
   PubMed Web of Science ®Google Scholar
• Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009 Aug 31;206(9):1913–1927.
   PubMed Web of Science ®Google Scholar
• Mammadova-Bach E, Gil-Pulido J, Sarukhanyan E, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3. Blood. 2020 Apr 2;135(14):1146–1160.
   PubMed Web of Science ®Google Scholar
• Mammadova-Bach E, Zigrino P, Brucker C, et al. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. JCI Insight. 2016 Sep 8;1(14):e88245.
   PubMed Web of Science ®Google Scholar
• Mitrugno A, Williams D, Kerrigan SW, et al. A novel and essential role for FcγRIIa in cancer cell-induced platelet activation. Blood. 2014 Jan 9;123(2):249–260.
   PubMed Web of Science ®Google Scholar
• Haemmerle M, Bottsford-Miller J, Pradeep S, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 May 2;126(5):1885–1896.
   PubMed Web of Science ®Google Scholar
• Cho MS, Noh K, Haemmerle M, et al. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. 2017 Sep 7;130(10):1235–1242.
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, LeVatte T, Liwski RS, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136(1):234–240.
   PubMed Web of Science ®Google Scholar
• Palacios-Acedo AL, Mezouar S, Mège D, et al. P2RY12-inhibitors reduce cancer-associated thrombosis and tumor growth in pancreatic cancers. Front Oncol. 2021;11:704945.
   PubMedGoogle Scholar
• Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009 Aug 12;302(6):649–658.
   PubMed Web of Science ®Google Scholar
• Bains SJ, Mahic M, Myklebust TA, et al. Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. J Clin Oncol. 2016 Jul 20;34(21):2501–2508.
   PubMed Web of Science ®Google Scholar
• Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016 Jun 1;2(6):762–769.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Yang T, Gan Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018 Mar 13;18(1):288.
   PubMedGoogle Scholar
• Guirguis-Blake JM, Evans CV, Perdue LA, et al. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the us preventive services task force. JAMA. 2022 Apr 26;327(16):1585–1597.
   PubMed Web of Science ®Google Scholar
• Kaufmann CC, Lyon AR, Wojta J, et al. Is P2Y12 inhibitor therapy associated with an increased risk of cancer? Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):100–104.
   PubMed Web of Science ®Google Scholar
• Anvari S, Osei E, Maftoon N. Interactions of platelets with circulating tumor cells contribute to cancer metastasis. Sci Rep. 2021 Jul 29;11(1):15477.
   PubMed Web of Science ®Google Scholar
• Egan K, Cooke N, Kenny D. Living in shear: platelets protect cancer cells from shear induced damage. Clin Exp Metastasis. 2014 Aug;31(6):697–704.
   PubMed Web of Science ®Google Scholar
• Echtler K, Konrad I, Lorenz M, et al. Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis. PLoS ONE. 2017;12(3):e0172788. DOI:10.1371/journal.pone.0172788
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013 Feb 1;339(6119):580–584.
   PubMed Web of Science ®Google Scholar
• Guo Y, Cui W, Pei Y, et al. Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-beta signaling pathway. Gynecol Oncol. 2019 Jun;153(3):639–650.
   PubMed Web of Science ®Google Scholar
• Angénieux C, Dupuis A, Gachet C, et al. Cell surface expression of HLA I molecules as a marker of young platelets. J Thromb Haemost. 2019 Sep;17(9):1511–1521.
   PubMed Web of Science ®Google Scholar
• Placke T, Örgel M, Schaller M, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012 Jan 15;72(2):440–448.
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999 Mar 15;59(6):1295–1300.
   PubMed Web of Science ®Google Scholar
• Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009 Oct 1;69(19):7775–7783.
   PubMed Web of Science ®Google Scholar
• Sadallah S, Schmied L, Eken C, et al. Platelet-derived ectosomes reduce NK cell function. J Immunol (Baltimore, Md : 1950). 2016 Sep 1;197(5):1663–1671. DOI:10.4049/jimmunol.1502658
   PubMed Web of Science ®Google Scholar
• Maurer S, Kropp KN, Klein G, et al. Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology. 2018;7(2):e1364827. DOI:10.1080/2162402X.2017.1364827
   PubMed Web of Science ®Google Scholar
• Danese S, de la Motte C, Reyes BM, et al. Cutting edge: t cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004 Feb 15;172(4):2011–2015.
   PubMed Web of Science ®Google Scholar
• Meikle CK, Meisler AJ, Bird CM, et al. Platelet-T cell aggregates in lung cancer patients: implications for thrombosis. PLoS ONE. 2020;15(8):e0236966. DOI:10.1371/journal.pone.0236966
   PubMed Web of Science ®Google Scholar
• Chapman LM, Aggrey AA, Field DJ, et al. Platelets present antigen in the context of MHC class I. J Immunol. 2012 Jul 15;189(2):916–923.
   PubMed Web of Science ®Google Scholar
• Rachidi S, Metelli A, Riesenberg B, et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol. 2017 May 5;2(11). DOI:10.1126/sciimmunol.aai7911
   PubMed Web of Science ®Google Scholar
• Metelli A, Wu BX, Riesenberg B, et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β. Sci Transl Med. 2020 Jan 8;12(525). DOI:10.1126/scitranslmed.aay4860
   PubMed Web of Science ®Google Scholar
• Zaslavsky AB, Adams MP, Cao X, et al. Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. Sci Rep. 2020 Nov 9;10(1):19296.
   PubMed Web of Science ®Google Scholar
• Riesenberg BP, Ansa-Addo EA, Gutierrez J, et al. Cutting edge: targeting thrombocytes to rewire anticancer immunity in the tumor microenvironment and potentiate efficacy of PD-1 blockade. J Immunol. 2019 Sep 1;203(5):1105–1110.
   PubMed Web of Science ®Google Scholar
• Zhou S, Liu M, Ren F, et al. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021 May 26;9(1):38.
   PubMed Web of Science ®Google Scholar
• Lutz MS, Klimovich B, Maurer S, et al. Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies. J Immunother Cancer. 2022 Feb;10(2):e003655.
   PubMed Web of Science ®Google Scholar
• Cao Y, Nishihara R, Qian ZR, et al. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology. 2016 Nov;151(5):879–892.e4.
   PubMed Web of Science ®Google Scholar
• Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021 Sep;5(9):951–967.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017 Mar 27;9(4):12.
   PubMed Web of Science ®Google Scholar
• Alvi M, Yaqoob A, Rehman K, et al. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022 Aug 01;8(1):12.
   Google Scholar
• Miao Y, Yang T, Yang S, et al. Protein nanoparticles directed cancer imaging and therapy. Nano Convergence. 2022 Jan 08;9(1):2.
   PubMed Web of Science ®Google Scholar
• Sharma S, Parveen R, Chatterji BP. Toxicology of nanoparticles in drug delivery. Curr Pathobiol Rep. 2021;9(4):133–144.
   PubMedGoogle Scholar
• Sieber S, Grossen P, Uhl P, et al. Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo. Nanomedicine. 2019 Apr;17:82–93.
   PubMed Web of Science ®Google Scholar
• Weber F, Ivan DC, Proulx ST, et al. Beyond trial and error: a systematic development of liposomes targeting primary macrophages. Adv NanoBiomed Res. 2021;1(3):2000098. DOI:10.1002/anbr.202000098
   Google Scholar
• Levchenko TS, Rammohan R, Lukyanov AN, et al. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 2002 Jun 20;240(1–2):95–102.
   PubMedGoogle Scholar
• Kozma GT, Mészáros T, Vashegyi I, et al. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano. 2019 Aug 27;13(8):9315–9324.
   PubMed Web of Science ®Google Scholar
• Petersen GH, Alzghari SK, Chee W, et al. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release. 2016 Jun 28;232:255–264.
   PubMed Web of Science ®Google Scholar
• Ni C, Fang J, Qian H, et al. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report. J Int Med Res. 2020 Dec;48(12):300060520974854.
   PubMed Web of Science ®Google Scholar
• Visco C, Pregnolato F, Ferrarini I, et al. Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: a systematic review and single-arm metanalysis. Crit Rev Oncol Hematol. 2021 Jul;163:103377.
   PubMed Web of Science ®Google Scholar
• Ghasemi K, Vaseghi G, Mansourian M. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: a network meta-analysis of metastatic breast cancer. J Oncol Pharm Pract. 2021 Mar;27(2):414–427.
   PubMed Web of Science ®Google Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009 Jan;33(1):129–139.
   PubMed Web of Science ®Google Scholar
• Kim HP, Gerhard B, Harasym TO, et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011 Jul;39(7):741–750.
   PubMed Web of Science ®Google Scholar
• Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010 Sep;34(9):1214–1223.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684–2692.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Lin TL, Uy GL, et al. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. J Hematol Oncol. 2021 Jul 13;14(1):110.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Goshua G, Patel KK, et al. Cost-effectiveness of liposomal cytarabine-daunorubicin (CPX-351) compared to conventional cytarabine-daunorubicin chemotherapy in acute myeloid leukemia. Blood. 2021;138(Supplement 1):113–113. DOI:10.1182/blood-2021-144992
   PubMedGoogle Scholar
• Mastrorilli G, Fiorentino F, Tucci C, et al. Cost analysis of platelet transfusion in Italy for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. Clinicoecon Outcomes Res. 2022;14:205–220.
   PubMed Web of Science ®Google Scholar
• Michael JV, Wurtzel JGT, Mao GF, et al. Platelet microparticles infiltrating solid tumors transfer miRnas that suppress tumor growth. Blood. 2017 Aug 3;130(5):567–580.
   PubMed Web of Science ®Google Scholar
• French SL, Butov KR, Allaeys I, et al. Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation. Blood Adv. 2020 Jul 14;4(13):3011–3023.
   PubMed Web of Science ®Google Scholar
• Ma Q, Bai J, Xu J, et al. Reshaping the inflammatory environment in rheumatoid arthritis joints by targeting delivery of berberine with platelet-derived extracellular vesicles. Adv NanoBiomed Res. 2021;1(11):2100115. DOI:10.1002/anbr.202100115
   Google Scholar
• Laffont B, Corduan A, Ple H, et al. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood. 2013 Jul 11;122(2):253–261.
   PubMed Web of Science ®Google Scholar
• Cacic D, Reikvam H, Nordgård O, et al. Platelet microparticles protect acute myelogenous leukemia cells against daunorubicin-induced apoptosis. Cancers (Basel). 2021;13(8):1870. DOI:10.3390/cancers13081870
   PubMed Web of Science ®Google Scholar
• Liang H, Yan X, Pan Y, et al. MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol Cancer. 2015 Mar 11;14(1):58.
   PubMed Web of Science ®Google Scholar
• Qu M, Zou X, Fang F, et al. Platelet-derived microparticles enhance megakaryocyte differentiation and platelet generation via miR-1915-3p. Nat Commun. 2020 Oct 2;11(1):4964.
   PubMed Web of Science ®Google Scholar
• Vismara M, Zarà M, Negri S, et al. Platelet-derived extracellular vesicles regulate cell cycle progression and cell migration in breast cancer cells. Biochim Biophys Acta, Mol Cell Res. 2021 Jan;1868(1):118886.
   PubMed Web of Science ®Google Scholar
• Muley H, Fadó R, Rodríguez-Rodríguez R, et al. Drug uptake-based chemoresistance in breast cancer treatment. Biochem Pharmacol. 2020 Jul;177:113959.
   PubMed Web of Science ®Google Scholar
• Xu P, Zuo H, Chen B, et al. Doxorubicin-loaded platelets as a smart drug delivery system: an improved therapy for lymphoma. Sci Rep. 2017 Feb 15;7(1):42632.
   PubMedGoogle Scholar
• Li QR, Xu HZ, Xiao RC, et al. Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery. Drug Deliv. 2022 Dec;29(1):937–949.
   PubMed Web of Science ®Google Scholar
• Wu YW, Huang CC, Changou CA, et al. Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. J Biomed Sci. 2020 Mar 23;27(1):45. DOI:10.1186/s12929-020-00633-2
   PubMed Web of Science ®Google Scholar
• Sarkar S, Alam MA, Shaw J, et al. Drug delivery using platelet cancer cell interaction. Pharm Res. 2013 Nov;30(11):2785–2794.
   PubMed Web of Science ®Google Scholar
• Ying M, Zhuang J, Wei X, et al. Remote-loaded platelet vesicles for disease-targeted delivery of therapeutics. Adv Funct Mater. 2018 May 30;28(22):1801032.
   PubMed Web of Science ®Google Scholar
• Li T, Chen T, Chen H, et al. Engineered platelet-based micro/nanomotors for cancer therapy. Small. 2021 Dec;17(52):e2104912.
   PubMed Web of Science ®Google Scholar
• Yu Y, Cheng Q, Ji X, et al. Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis. Sci Adv. 2022 Dec 9;8(49):eadd3599.
   PubMed Web of Science ®Google Scholar
• Hu Q, Sun W, Qian C, et al. Relay drug delivery for amplifying targeting signal and enhancing anticancer efficacy. Adv Mater. 2017;29(13):1605803. DOI:10.1002/adma.201605803
   Web of Science ®Google Scholar
• Matyszewska D. The influence of charge and lipophilicity of daunorubicin and idarubicin on their penetration of model biological membranes - Langmuir monolayer and electrochemical studies. Biochim Biophys Acta Biomembr. 2020 Feb 1;1862(2):183104.
   PubMed Web of Science ®Google Scholar
• Andreev E, Brosseau N, Carmona E, et al. The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. Sci Rep. 2016 Feb 10;6(1):20508.
   PubMed Web of Science ®Google Scholar
• Gaertner F, Ahmad Z, Rosenberger G, et al. Migrating platelets are mechano-scavengers that collect and bundle bacteria. Cell. 2017 Nov 30;171(6):1368–1382.e23.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Horioka K, Hasebe T, et al. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor-platelet interactions. Int J Cancer. 2022 May 15;150(10):1640–1653.
   PubMed Web of Science ®Google Scholar
• Li X, Lovell JF, Yoon J, et al. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020 Nov;17(11):657–674.
   PubMed Web of Science ®Google Scholar
• Rao L, Bu L-L, Ma L, et al. Platelet-facilitated photothermal therapy of head and neck squamous cell carcinoma. Angewandte Chemie. 2018;57(4):986–991. DOI:10.1002/anie.201709457
   Google Scholar
• Zhang Y, Sun Y, Dong X, et al. A platelet intelligent vehicle with navigation for cancer photothermal-chemotherapy. ACS Nano. 2022 Apr 26;16(4):6359–6371.
   PubMed Web of Science ®Google Scholar
• Dai L, Gu N, Chen BA, et al. Human platelets repurposed as vehicles for in vivo imaging of myeloma xenotransplants. Oncotarget. 2016 Apr 19;7(16):21076–21090.
   PubMedGoogle Scholar
• Xu P, Zuo H, Zhou R, et al. Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget. 2017 Aug 29;8(35):58322–58337. DOI:10.18632/oncotarget.16871
   PubMedGoogle Scholar
• Fan X, Wang K, Lu Q, et al. Surface-anchored tumor microenvironment-responsive protein nanogel-platelet system for cytosolic delivery of therapeutic protein in the post-surgical cancer treatment. Acta Biomater. 2022 Dec;154:412–423.
   PubMed Web of Science ®Google Scholar
• Yap ML, McFadyen JD, Wang X, et al. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics. 2019;9(4):1154–1169. DOI:10.7150/thno.29146
   PubMed Web of Science ®Google Scholar
• Li J, Sharkey CC, Wun B, et al. Genetic engineering of platelets to neutralize circulating tumor cells. J Control Release. 2016 Apr 28;228:38–47.
   PubMed Web of Science ®Google Scholar
• Ortiz-Otero N, Marshall JR, Lash BW, et al. Platelet mediated TRAIL delivery for efficiently targeting circulating tumor cells. Nanoscale Adv. 2020 Sep 16;2(9):3942–3953.
   PubMed Web of Science ®Google Scholar
• Zhao W, Li T, Long Y, et al. Self-promoted albumin-based nanoparticles for combination therapy against metastatic breast cancer via a hyperthermia-induced “platelet bridge”. ACS Appl Mater Interfaces. 2021 Jun 9;13(22):25701–25714.
   PubMed Web of Science ®Google Scholar
• Li S, Li L, Lin X, et al. Targeted inhibition of tumor inflammation and tumor-platelet crosstalk by nanoparticle-mediated drug delivery mitigates cancer metastasis. ACS Nano. 2022 Jan 25;16(1):50–67.
   PubMed Web of Science ®Google Scholar
• Guo R, Deng M, He X, et al. Fucoidan-functionalized activated platelet-hitchhiking micelles simultaneously track tumor cells and remodel the immunosuppressive microenvironment for efficient metastatic cancer treatment. Acta Pharm Sin B. 2022 Jan;12(1):467–482.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun W, Ye Y, et al. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat Biomed Eng. 2017 Jan 23;1(2):0011.
   Web of Science ®Google Scholar
• Lu Q, Ye H, Wang K, et al. Bioengineered platelets combining chemotherapy and immunotherapy for postsurgical melanoma treatment: internal core-loaded doxorubicin and external surface-anchored anti-PD-L1 antibody backpacks. Nano Lett. 2022 Apr 13;22(7):3141–3150.
   PubMed Web of Science ®Google Scholar
• Hu Q, Sun W, Wang J, et al. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. Nat Biomed Eng. 2018 Nov;2(11):831–840. DOI:10.1038/s41551-018-0310-2
   PubMed Web of Science ®Google Scholar
• Hu Q, Li H, Archibong E, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021 Sep;5(9):1038–1047.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang J, Chen Z, et al. Engineering PD-1-presenting platelets for cancer immunotherapy. Nano Lett. 2018 Sep 12;18(9):5716–5725.
   PubMed Web of Science ®Google Scholar
• Li Z, Ding Y, Liu J, et al. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nat Commun. 2022 Apr 6;13(1):1845.
   PubMed Web of Science ®Google Scholar
• Li H, Wang Z, Chen Z, et al. Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. Nat Commun. 2021 May 13;12(1):2773. DOI:10.1038/s41467-021-22674-3
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen X, Wang B, et al. Engineering Platelets with PDL1 antibodies and iron oxide nanoparticles for postsurgical cancer immunotherapy. ACS Appl Bio Mater. 2023 Jan 16;6(1):257–266.
   PubMedGoogle Scholar
• Han X, Chen J, Chu J, et al. Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody. J Control Release. 2019 Jun 28;304:233–241.
   PubMed Web of Science ®Google Scholar
• Hu CM, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015 Oct 1;526(7571):118–121.
   PubMed Web of Science ®Google Scholar
• Wang H, Wu J, Williams GR, et al. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J Nanobiotechnology. 2019 May 13;17(1):60.
   PubMedGoogle Scholar
• Zhou M, Lai W, Li G, et al. Platelet membrane-coated and VAR2CSA malaria protein-functionalized nanoparticles for targeted treatment of primary and metastatic cancer. ACS Appl Mater Interfaces. 2021 Jun 9;13(22):25635–25648.
   PubMed Web of Science ®Google Scholar
• Mei D, Gong L, Zou Y, et al. Platelet membrane-cloaked paclitaxel-nanocrystals augment postoperative chemotherapeutical efficacy. J Control Release. 2020 Aug 10;324:341–353.
   PubMed Web of Science ®Google Scholar
• Pan V, Siva PN, Modery-Pawlowski CL, et al. Targeted killing of metastatic cells using a platelet-inspired drug delivery system [10.1039/C5RA05339K]. RSC Adv. 2015;5(57):46218–46228. DOI:10.1039/C5RA05339K
   Web of Science ®Google Scholar
• Li J, Ai Y, Wang L, et al. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials. 2016 Jan;76:52–65.
   PubMed Web of Science ®Google Scholar
• Hu Q, Sun W, Qian C, et al. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015 Nov 25;27(44):7043–7050.
   PubMed Web of Science ®Google Scholar
• Kim MW, Lee G, Niidome T, et al. Platelet-like gold nanostars for cancer therapy: the ability to treat cancer and evade immune reactions. Front Bioeng Biotechnol. 2020;8:133.
   PubMed Web of Science ®Google Scholar
• Yang H, Ding Y, Tong Z, et al. Ph-responsive hybrid platelet membrane-coated nanobomb with deep tumor penetration ability and enhanced cancer thermal/chemodynamic therapy. Theranostics. 2022;12(9):4250–4268. DOI:10.7150/thno.68996
   PubMed Web of Science ®Google Scholar
• Pei W, Huang B, Chen S, et al. Platelet-mimicking drug delivery nanoparticles for enhanced chemo-photothermal therapy of breast cancer. Int J Nanomedicine. 2020;15:10151–10167.
   PubMed Web of Science ®Google Scholar
• Ye H, Wang K, Wang M, et al. Bioinspired nanoplatelets for chemo-photothermal therapy of breast cancer metastasis inhibition. Biomaterials. 2019 Jun;206:1–12.
   PubMed Web of Science ®Google Scholar
• Chen M, Wang P, Jiang D, et al. Platelet membranes coated gold nanocages for tumor targeted drug delivery and amplificated low-dose radiotherapy. Front Oncol. 2021;11:793006.
   PubMed Web of Science ®Google Scholar
• Bahmani B, Gong H, Luk BT, et al. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat Commun. 2021 Mar 31;12(1):1999. DOI:10.1038/s41467-021-22311-z
   PubMed Web of Science ®Google Scholar
• Hu Q, Qian C, Sun W, et al. Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus. Adv Mater. 2016 Nov;28(43):9573–9580.
   PubMed Web of Science ®Google Scholar
• Zhou L, Feng W, Mao Y, et al. Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic tumor therapy by glutamine deprivation and cascading thrombosis. Bioact Mater. 2023 Jun;24:26–36.
   PubMed Web of Science ®Google Scholar
• Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5341–5347.
   PubMed Web of Science ®Google Scholar
• Bilalis P, Tziveleka L-A, Varlas S, et al. Ph-Sensitive nanogates based on poly(l-histidine) for controlled drug release from mesoporous silica nanoparticles [10.1039/C5PY01841B]. Polym Chem. 2016;7(7):1475–1485. DOI:10.1039/C5PY01841B
   Web of Science ®Google Scholar
• Ho JD, Yeh R, Sandstrom A, et al. Crystal structure of human aquaporin 4 at 1.8 a and its mechanism of conductance. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7437–7442.
   PubMed Web of Science ®Google Scholar
• Girardi E, César-Razquin A, Lindinger S, et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat Chem Biol. 2020 Apr;16(4):469–478.
   PubMed Web of Science ®Google Scholar
• Ueda K, Hosokawa M, Iwakawa S. Cellular uptake of decitabine by equilibrative nucleoside transporters in HCT116 Cells. Biol Pharm Bull. 2015;38(8):1113–1119.
   PubMed Web of Science ®Google Scholar
• Arimany-Nardi C, Errasti-Murugarren E, Minuesa G, et al. Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Br J Pharmacol. 2014 Aug;171(16):3868–3880.
   PubMed Web of Science ®Google Scholar
• Damaraju VL, Mowles D, Yao S, et al. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids. 2012;31(3):236–255. DOI:10.1080/15257770.2011.652330
   PubMed Web of Science ®Google Scholar
• Candelaria M, Corrales-Alfaro C, Gutiérrez-Hernández O, et al. Expression levels of human equilibrative nucleoside transporter 1 and deoxycytidine kinase enzyme as prognostic factors in patients with acute myeloid leukemia treated with cytarabine. Chemotherapy. 2016;61(6):313–318. DOI:10.1159/000445370
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Martínez-Cuadrón D, Solana-Altabella A, et al. Systematic review of pharmacogenetics of ABC and SLC transporter genes in acute myeloid leukemia. Pharmaceutics. 2022 Apr 17;14(4). DOI:10.3390/pharmaceutics14040878
   PubMed Web of Science ®Google Scholar
• Belkouz A, Labeur TA, Dierks J, et al. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019 Sep;141:82–94.
   PubMed Web of Science ®Google Scholar
• Bird NT, Elmasry M, Jones R, et al. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. Br J Surg. 2017 Mar;104(4):328–336.
   PubMed Web of Science ®Google Scholar
• Buelow DR, Anderson JT, Pounds SB, et al. DNA methylation-based epigenetic repression of SLC22A4 promotes resistance to cytarabine in acute myeloid leukemia. Clin Transl Sci. 2021 Jan;14(1):137–142.
   PubMed Web of Science ®Google Scholar
• Drenberg CD, Gibson AA, Pounds SB, et al. OCTN1 is a high-affinity carrier of nucleoside analogues. Cancer Res. 2017 Apr 15;77(8):2102–2111.
   PubMed Web of Science ®Google Scholar
• Burkhart JM, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood. 2012 Oct 11;120(15):e73–82.
   PubMed Web of Science ®Google Scholar
• Uslu D, Abas BI, Demirbolat GM, et al. Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells. Mol Divers. 2022 Dec 28. DOI:10.1007/s11030-022-10591-6
   PubMed Web of Science ®Google Scholar
• Kodama T, Takehara T, Hikita H, et al. BH3-only activator proteins bid and bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-Xl deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem. 2011 Apr 22;286(16):13905–13913.
   PubMed Web of Science ®Google Scholar
• Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007 Mar 23;128(6):1173–1186.
   PubMed Web of Science ®Google Scholar
• Guo L, Shen S, Rowley JW, et al. Platelet MHC class I mediates CD8+ T-cell suppression during sepsis. Blood. 2021 Aug 5;138(5):401–416.
   PubMed Web of Science ®Google Scholar
• Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007 Mar;97(3):425–434.
   PubMed Web of Science ®Google Scholar
• Ferreira PM, Bozbas E, Tannetta SD, et al. Mode of induction of platelet-derived extracellular vesicles is a critical determinant of their phenotype and function. Sci Rep. 2020 Oct 22;10(1):18061.
   PubMed Web of Science ®Google Scholar
• Maurer-Spurej E, Larsen R, Labrie A, et al. Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress. Transfus Apher Sci. 2016 Aug;55(1):35–43.
   PubMed Web of Science ®Google Scholar
• Nasiri S. Infusible platelet membrane as a platelet substitute for transfusion: an overview. Blood Transfus. 2013 Jul;11(3):337–342.
   PubMed Web of Science ®Google Scholar
• Marcoux G, Magron A, Sut C, et al. Platelet-derived extracellular vesicles convey mitochondrial DAMPs in platelet concentrates and their levels are associated with adverse reactions. Transfusion. 2019 Jul;59(7):2403–2414.
   PubMed Web of Science ®Google Scholar
• Rank A, Nieuwland R, Crispin A, et al. Clearance of platelet microparticles in vivo. Platelets. 2011;22(2):111–116. DOI:10.3109/09537104.2010.520373
   PubMed Web of Science ®Google Scholar
• Papa AL, Jiang A, Korin N, et al. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019 Feb 13;11(479). DOI:10.1126/scitranslmed.aau5898
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu Y, Wei X, et al. Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model. Acta Pharm Sin B. 2022 Aug;12(8):3427–3447.
   PubMed Web of Science ®Google Scholar
• Johnson L, Lei P, Waters L, et al. Identification of platelet subpopulations in cryopreserved platelet components using multi-colour imaging flow cytometry. Sci Rep. 2023 Jan 21;13(1):1221.
   PubMed Web of Science ®Google Scholar